share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  07/10 08:04
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.
Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.
vivos therapeutics公司是纳斯达克股票市场上的一家公司，其于2024年7月10日报道称已获得纳斯达克听证会议小组的批准，条件是截至2024年8月15日展示符合股东权益要求。该公司此前已被告知未达到2024年3月31日的纳斯达克最低权益要求的不合规状态，最小权益金额为25百万美元。vivos therapeutics公司通过在2024年6月10日完成了750百万美元的定向增发，解决了这一问题，随后于2024年6月27日会见了听证会议小组。该公司正在积极努力保持合规，探索额外的股权融资，并预计得到战略营销和分销联盟带来营业收入和股权的积极影响。然而，存在未能保持必要股权水平的风险，这可能导致退市并对公司的股票价格和运营产生重大影响。
vivos therapeutics公司是纳斯达克股票市场上的一家公司，其于2024年7月10日报道称已获得纳斯达克听证会议小组的批准，条件是截至2024年8月15日展示符合股东权益要求。该公司此前已被告知未达到2024年3月31日的纳斯达克最低权益要求的不合规状态，最小权益金额为25百万美元。vivos therapeutics公司通过在2024年6月10日完成了750百万美元的定向增发，解决了这一问题，随后于2024年6月27日会见了听证会议小组。该公司正在积极努力保持合规，探索额外的股权融资，并预计得到战略营销和分销联盟带来营业收入和股权的积极影响。然而，存在未能保持必要股权水平的风险，这可能导致退市并对公司的股票价格和运营产生重大影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息